4DMedical Raises $100M+ to Accelerate U.S. Rollout of Software-Based Lung Imaging

4DMedical has secured more than US$100 million (AU$150 million) in new institutional funding, strengthening its balance sheet and accelerating the U.S. rollout of its FDA-cleared CT:VQ™ respiratory imaging platform. The raise positions the Australia-listed company to scale adoption across leading health systems while expanding research and development to extend its technological lead in software-based lung imaging.

Founded as a specialist in advanced cardiothoracic imaging, 4DMedical develops software that applies proprietary algorithms and artificial intelligence to standard clinical scans. Its platform extracts quantitative, regional lung-function data from routine imaging, offering clinicians a functional view of ventilation and perfusion that goes beyond traditional structural assessment.

The company’s flagship product, CT:VQ™, is a software-as-a-service platform that derives ventilation and perfusion insights directly from standard CT scans. Within just four months of FDA clearance, the product was deployed at four major U.S. academic medical centers: Stanford Health Care, Cleveland Clinic, University of Miami Health System, and UC San Diego Health. The speed of adoption highlights growing clinical demand for functional lung data to support diagnosis, longitudinal disease monitoring, treatment selection, and surgical planning.

“This is an extraordinarily important and validating milestone,” said Andreas Fouras, Founder and CEO of 4DMedical. “It reflects global recognition of our technological leadership, the clinical relevance of products such as CT:VQ™, and the significant growth opportunity ahead in the U.S. market. With strengthened institutional backing and balance sheet flexibility, we are positioned to scale adoption, accelerate R&D, deepen strategic partnerships, and lead the global market for software-based lung imaging.”

Proceeds from the raise will be used to expand 4DMedical’s commercial footprint across U.S. academic medical centers and integrated delivery networks, while also enhancing customer success, training, and clinical enablement programs to drive consistent real-world use. Additional investment will support ongoing research into new functional lung imaging applications and provide operational flexibility to sustain long-term health system partnerships.

Following the financing, 4DMedical reported a pro forma cash position exceeding US$130 million (AU$200 million), giving the company significant runway as it supports a growing installed base. Delivered through a SaaS model designed to integrate with existing hospital IT and imaging infrastructure, the platform is supported by strategic partnerships, including with Philips, to enable enterprise-scale deployment.

Collectively, these developments position 4DMedical as a central player in the shift toward functional, software-driven lung imaging, bringing quantified cardiopulmonary insights into routine clinical care at scale.

Click here for the original news story.